N1VS34 Stock Overview
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
Novartis AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF51.00 |
| 52 Week High | CHF54.20 |
| 52 Week Low | CHF45.60 |
| Beta | 0.47 |
| 1 Month Change | 7.03% |
| 3 Month Change | -2.95% |
| 1 Year Change | -0.31% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 19.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| N1VS34 | BR Pharmaceuticals | BR Market | |
|---|---|---|---|
| 7D | 4.1% | 1.8% | 0.9% |
| 1Y | -0.3% | -16.9% | 15.0% |
Return vs Industry: N1VS34 exceeded the BR Pharmaceuticals industry which returned -20.6% over the past year.
Return vs Market: N1VS34 underperformed the BR Market which returned 13.7% over the past year.
Price Volatility
| N1VS34 volatility | |
|---|---|
| N1VS34 Average Weekly Movement | 2.4% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in BR Market | 8.8% |
| 10% least volatile stocks in BR Market | 2.3% |
Stable Share Price: N1VS34 has not had significant price volatility in the past 3 months.
Volatility Over Time: N1VS34's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 76,057 | Vas Narasimhan | www.novartis.com |
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
Novartis AG Fundamentals Summary
| N1VS34 fundamental statistics | |
|---|---|
| Market cap | R$1.02t |
| Earnings (TTM) | R$46.59b |
| Revenue (TTM) | R$244.21b |
21.9x
P/E Ratio4.2x
P/S RatioIs N1VS34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| N1VS34 income statement (TTM) | |
|---|---|
| Revenue | US$47.73b |
| Cost of Revenue | US$12.12b |
| Gross Profit | US$35.61b |
| Other Expenses | US$26.51b |
| Earnings | US$9.11b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 18, 2024
| Earnings per share (EPS) | 4.46 |
| Gross Margin | 74.61% |
| Net Profit Margin | 19.08% |
| Debt/Equity Ratio | 64.2% |
How did N1VS34 perform over the long term?
See historical performance and comparison